SunRISe-5

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

TAR-200OngoingActive not recruitingPhase 3Open NCT06211764 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…

SunRISe-5 · Trial Tracker · ComplyRx